Antibodies led to a condition called thrombotic thrombocytopenia, which caused both clots and abnormal bleeding. Researchers suggested naming the newly identified variant in these patients as “vaccine-induced immune thrombotic thrombocytopenia,” or VITT.
Various theories have been offered by scientists that touch upon the immune response. The AstraZeneca vaccine employs a chimpanzee adenovirus to carry DNA in recipients to spark an immune response against coronovirus. Laboratory studies have suggested that chimp virus or DNA may be the cause of the problem. Some researchers have suggested that the bleeding from the vaccine, mixed with the vaccine, may put platelets in the cross-hairs of the immune system.
Dr. Greincher called the theories admirable but unproven.
The article describes specialized blood tests that can be used to diagnose the disorder, and distinguish it from other, more common clotting problems that are unrelated to the vaccine. The research team suggested treatment with a blood product called intravenous immune globulin, which is used to treat various immune disorders. Dr. Greincher compared the treatment to fire.
Anti-coagulants or blood thinning drugs may also be administered. But researchers recommended against prescribing a commonly used heparin – because the condition related to the vaccine is similar to a very severe reaction that rarely occurs in people given heparin.
The second report, from Norway, The described five patients, one male and four female health care workers ages 32 to 54, who had clots and bleeding seven to 10 days after receiving the AstraZeneca vaccine. Four had severe clots in the brain, and three died. Severe headaches were among his initial symptoms. Like German patients, all had high levels of antibodies that could activate platelets.
The Norway team also recommended treatment with intravenous immune globulin. Researchers said the disorder was rare, but “a new phenomenon with devastating effects for otherwise healthy young adults,” and they suggested that it may be more common than previous studies of the AstraZeneca vaccine.
on Friday, European regulators also said they were reviewing the report Some blood clotting cases in people receiving the Johnson & Johnson vaccine. In the United States, federal agencies are investigating a different type of report Abnormal blood disorder Incorporating an early decline in platelets that emerged among a few dozen people who had received either Pfizer-BioNotech or Modern vaccines.
Benjamin Muller and Melissa Eddy contributed.